Avelos Therapeutics is at the forefront of innovative cancer treatment, focusing on biomarker-driven drug research and the development of targeted therapeutics. The company emphasizes three primary research areas: DNA Damage Response (DDR), Cell Cycle & Checkpoints, and Synthetic Lethality. The DDR is crucial for maintaining genomic stability, and its dysfunction is a hallmark of cancer. Avelos aims to leverage this by developing therapies that inhibit DDR mechanisms, which can effectively target cancers with specific genetic vulnerabilities, such as those with BRCA mutations. Additionally, the company addresses the limitations of traditional cytotoxic chemotherapies by focusing on more selective drugs that target cancer-specific defects, thereby reducing toxicity and overcoming drug resistance.

In its pursuit of novel therapies, Avelos Therapeutics is pioneering a synthetic lethality platform known as "SMILOG" (Small Molecules Inducing Lethality in OncoGenic cells). This platform aims to identify new synthetic lethal targets through a combination of genetic analysis of tumor cells and profiling of target-specific inhibitors. By exploiting the concept of synthetic lethality, where the simultaneous inactivation of two genes leads to cancer cell death while sparing normal cells, Avelos is developing next-generation onco-therapeutics that address unmet medical needs in cancer treatment. This innovative approach positions Avelos as a leader in the quest for effective cancer therapies that minimize side effects and improve patient outcomes.

South Korea

Avelos Therapeutics is a precision medicine company in the clinical stage that finds, creates, and sells targeted therapeutics. They are the developer of biomarker-driven anti-cancer targeted therapies and have raised a total funding of $8M over 1 round from 7 investors.

Avelos Therapeutics

Company Details